**Proteins** 

# GSK1292263

Cat. No.: HY-12066 CAS No.: 1032823-75-8 Molecular Formula:  $C_{23}H_{28}N_4O_4S$ Molecular Weight: 456.56 GPR119 Target:

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Powder


2 years

3 years

-80°C In solvent 2 years

-20°C

-20°C 1 year



**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO : ≥ 20 mg/mL (43.81 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1903 mL	10.9515 mL	21.9029 mL
	5 mM	0.4381 mL	2.1903 mL	4.3806 mL
	10 mM	0.2190 mL	1.0951 mL	2.1903 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2 mg/mL (4.38 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

Description  $\mathsf{GSK-}1292263$  is an orally available  $\mathsf{GPR119}$  agonist with  $\mathsf{pEC}_{50}\mathsf{s}$  of 6.9 and 6.7 for human and rat  $\mathsf{GPR119}$ , respectively.  $\mathsf{GSK-}1292263$  is an orally available  $\mathsf{GPR119}$  agonist with  $\mathsf{pEC}_{50}\mathsf{s}$  of 6.9 and 6.7 for human and rat  $\mathsf{GPR119}$ , respectively.  $\mathsf{GSK-}1292263$  is an orally available  $\mathsf{GPR119}$  agonist with  $\mathsf{pEC}_{50}\mathsf{s}$  of 6.9 and 6.7 for human and rat  $\mathsf{GPR119}$ , respectively.

1292263 can be used for the research of type 2 diabetes mellitus (T2DM)<sup>[1]</sup>.

In Vivo GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male neonatal Streptozotocin (STZ)-induced SD rats (7 weeks of age)<sup>[2]</sup> Dosage: 30 mg/kg

Administration:	Orally given; once a day for 2 weeks
Result:	The AUC of plasma glucose (AUC <sub>PG</sub> ) in the single treatment of the GSK1292263 group wa numerically lower than that of the vehicle group, but the effect was modest.

## **CUSTOMER VALIDATION**

- J Exp Clin Cancer Res. 2018 Nov 29;37(1):295.
- FASEB J. 2016 Jan;30(1):324-35.
- College of Pharmacy. Seoul National University. 2015 Aug.

See more customer validations on www.MedChemExpress.com

### **REFERENCES**

[1]. X. Zhu, et al. GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment.

[2]. Koji Matsumoto, et al. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats. J Pharmacol Exp The

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com\\$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA